Ghayal Once again has been proved a successful comeback for the vetran actor Sunny Deol. His fans have waited a lot for his movie in own’s style. Its well-known fact that Ghayal was hit on the box office and its sequel has also defeted the Ghayal collections on numbers. The movie is still doing an above average business in India.
Occupancy to watch Ghayal Once Again was seen limited to the North Indian audience. On the initial day, the occupancy has arrived to 50-90% in most of the theaters of UP, Punjab, Haryana and Delhi. With the sequel moving forwards, the audience seems to be targetted as the collections went down. During the last 6 days, the film has faced out different numbers when it comes to occupancy in the cinemas.ghayal once again 6 days collections
Film needs a kick off this friday to reach out its initial goals of crossing and being categorised as a hit film in the Bollywood. Normally movies aggergating more than 50 crores by the end of the screening are categorised as a good movie. Although Ghayal Once Again collections have crossed the figure of 5 crores in overseas market which is yet a positive sign.
|Total Domestic Collection||26.85 cr|
|Total Overseas Collection||05.00 cr|
|Total Worldwide Collection||36.85 cr|
The total Ghayal Once Again collections comes to 36 crore rupees during a span of 6 days only. It’s still shortfalling from achieving a figure of 50 crores by 14 crore rupees. Our analysis states that after the release of Neerja movie, it would be hard for the film to sustain on box office.
Film has four day total of 26.85 cr nett from the Indian market only which was a great figure, getting low in numbers specially on the important days is still a thing to worry for the talkie.
Throughout the period of 6 days, the movie has faced some lows but still able to sustain from the odds by beating out most of figures in the Bollywood, and being a movie performing better than Kya Kool Hai Hum 3 and Mastizaade. GOA would be a landmark comeback for Sunny Deol. Click here to read Ghayal Once Again Review.